Products

Basilea is currently marketing Toctino® (alitretinoin), the only approved treatment for severe chronic hand eczema unresponsive to potent topical steroids, in Denmark, Finland, France, Germany, Norway, Switzerland and the United Kingdom. Basilea has entered into distribution agreements for Toctino® for selected European markets, Canada, Israel, Mexico and the Republic of Korea.